First FDA Approval for FSGS Treatment Causes Surge in Rare Kidney Disease Stocks

On the Nasdaq, Travere Therapeutics (TRAVERE THERAPEUTICS INC: TVTX) surged 38% intraday on April 14, trading at $41.53 in a dramatic rally. Trading volume reached 9.44 million shares, and market capitalization climbed to approximately $3.8 billion (about KRW 5.2 trillion), adding roughly $2.3 billion (KRW 3.2 trillion) in a single day.

The previous day, the U.S. FDA granted full approval to the company’s rare kidney disease treatment FILSPARI, expanding its indication to include focal segmental glomerulosclerosis (FSGS) and making it the first approved therapy for this condition—news that ignited investor enthusiasm. ()

On April 14, the day after approval, TVTX broke above the $40 mark to reach a 52-week high and ranked among the top gainers on U.S. exchanges with a nearly 40% one-day jump. ()

Travere Therapeutics is a U.S. biotech company focused on developing therapies for rare kidney, liver, and metabolic diseases. Its flagship product, FILSPARI, is already commercialized for patients with IgA nephropathy (IgAN). ()

With the FSGS approval in hand, the company plans to broaden FILSPARI’s revenue base while accelerating clinical trials of its pipeline of rare metabolic disease candidates to secure mid- to long-term growth drivers. ()